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The mechanism of edema formation in the nephrotic
syndrome has long been a source of controversy. In this
review, through the construct of Starling’s forces, we
examine the roles of albumin, intravascular volume, and
neurohormones on edema formation and highlight the
evolving literature on the role of primary sodium absorption
in edema formation. We propose that a unifying mechanism
of sodium retention is present in the nephrotic syndrome
regardless of intravascular volume status and is due to the
activation of epithelial sodium channel by serine proteases in
the glomerular filtrate of nephrotic patients. Finally, we assert
that mechanisms in addition to sodium retention are likely
operant in the formation of nephrotic edema.
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Edema is the classic clinical presentation of the nephrotic
syndrome. The mechanisms of edema formation in the
nephrotic syndrome have long been a subject of investigation
and are continually debated. The ‘underfill’ hypothesis states
that a decrement in oncotic pressure leads to excess filtration
of fluid from the intravascular space to the interstitial space,
causing hypovolemia, renal hypoperfusion, activation of the
renin–angiotensin–aldosterone system, and secondary renal
sodium retention. The ‘overfill’ hypothesis states that the
nephrotic syndrome causes primary renal sodium retention,
leading to edema. The purpose of this review is to describe
in detail the state of current knowledge in this area and
ultimately to provide a unifying model of edema formation
in the nephrotic syndrome. We will individually discuss the
contribution of plasma oncotic pressure, the state of
intravascular volume, perturbation in hormonal systems,
and the role of primary sodium retention by the kidney using
the framework provided by Starling:
Jv ¼ Kf ð½Pc  Pi  s½pc  piÞ
K Jv is the net fluid movement between compartments.
K [PcPi]: Capillary-interstitial hydrostatic pressure
K s: reflection coefficient to proteins; which varies between
0 and 1 and reflects in this particular context some
attribute of the permeability of capillaries to albumin and
other large proteins
K [pcpi]: oncotic pressure (c is capillary and I is
interstitial)
K Kf¼ overall filtration permeability constant to volume
flow (hydraulic conductivity and includes a term for
surface area)
Both Kf and s are measures of vascular permeability. Kf,
the product of hydraulic conductance and capillary surface
area, is essentially a measure of capillary permeability to
volume flow.1 When the capillary is modeled as a surface
with many pores, then its hydraulic conductance depends on
the number of pores present, the radius of the pores, and the
thickness of the capillary wall.1 However, this parameter is
not a true constant, rather it is known to increase in response
to increases in intravascular pressure2,3 and hyperglycemia.4
Also, s is some measure of the permeability of the capillary to
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proteins. A s value of 1 signifies that a capillary is completely
impermeable to proteins, whereas a value of 0 signifies
complete permeability to proteins.1 This parameter has been
shown to decrease in response to inflammatory mediators
such as histamine and bradykinin.5 Although an increase in
Kf does not necessarily produce a change in s,
4 an decrease
in s (as with an increase in pore size) necessitates an increase
in Kf. Further complicating matters is that vascular perme-
ability is calculated rather than directly measured. It is
therefore difficult to separate changes in permeability to
different substances from current experiments in large part
because of the lack of knowledge of the actual path that fluid
flow takes across a complex biological structure such as a
capillary. For this reason, for the remainder of the review, we
will refer to Kf and s under the general term of vascular
permeability.
CHANGES IN ONCOTIC PRESSURE GRADIENTS [pcpi]
A fundamental aspect of the ‘underfill’ theory is that a
decrement in plasma albumin (and hence oncotic pressure)
reduces the intravascular-to-interstitial albumin gradient
producing an increase in the driving force for fluid filtration
out of the intravascular space into the interstitial space.
Several studies have addressed this important issue.
Hypoalbuminemia is accompanied by a parallel decrease in
interstitial albumin
Joles6 showed that analbuminemic Nagase rats had no
difference in transcapillary colloid osmotic pressure gradient
when compared with Sprague-Dawley rats of similar age
owing to increases in nonalbumin proteins in the Nagase rats.
Fiorotto and Coward7 utilized a starvation model of hypo-
proteinemia to study the driving forces for edema formation
in rats. The experiments showed that as serum oncotic
pressure decreases there is a parallel decrease in interstitial
oncotic pressure of greater magnitude (Figure 1). Also
notable was that the normally negative interstitial hydrostatic
pressure approached zero at the time of edema formation.
For these reasons, despite the decrement in plasma oncotic
pressure in the protein malnourished rats, the net driving
force for edema formation was not significantly different
from control rats. Preservation of the oncotic pressure
gradient due to parallel decreases in serum and interstitial
oncotic pressures has also been demonstrated in humans
with the nephrotic syndrome.8–10 Finally, in a review of 21
cases of congenital analbuminemia by Russi and Weigand,11
43% had no edema, whereas 38% had only mild ankle
edema. Hence, a reduction in the serum to interstitial oncotic
pressure gradient due to hypoalbuminemia is not supported
by existing data.
Mechanisms for decrease in interstitial albumin
It has been proposed by Aukland and Nicolaysen12 that
two safety factors protect against edema formation in the
presence of hypoalbuminemia. An increase in filtration
of fluid from the intravascular space to the interstitial space
will dilute or ‘washdown’ the interstitial protein concentra-
tion. In addition, an increase in fluid delivery to the
interstitial space will produce an increase in lymphatic flow
that will ‘washout’ interstitial proteins by bulk flow. Both
washdown and washout, as may occur with loss of fluid
from the intravascular to interstitial space in hypoprotein-
emia, serve to maintain the plasma to interstitial protein
ratio close to normal and thus defend against edema. Edema
formation would follow when the interstitial protein
concentration was reduced to zero and no further reduction
could occur in response to further intravascular protein
decline.
Koomans et al.13 studied the influence of colloid osmotic
pressure and plasma protein concentration on blood volume
and blood pressure in nephrotic patients and those with
chronic renal failure who were admitted to the hospital with
extracellular fluid volume (ECFV) expansion. As compared
with the chronic renal failure patients, the nephrotic patients
had significantly lower plasma protein and oncotic pressures
and higher hematocrits. An elevation of the ECFV to 300% of
normal produced no significant change in blood volume
compared with baseline in nephrotic patients; blood pressure
similarly was not significantly different. In contrast, the blood
volume and blood pressure were significantly elevated in the
chronic renal failure patients at an ECFV of 200% above
baseline. Thus, the ECFV excess expands both the intravas-
cular and interstitial space in chronic renal failure, whereas
the excess is largely confined to the interstitial space in
nephrotic patients. The authors hypothesize that nephrotic
patients have no edema despite marked hypoproteinemia at
normal ECVF because of the protective effects of interstitial
protein washdown and washout. They further hypothesize
that expansion of the ECFV to 300% of normal does not raise
the intravascular volume because the interstitial protein
concentration is near zero and no further washdown or
washout can occur.
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Figure 1 |As serum oncotic pressure declines, there is a
parallel decline in interstitial oncotic pressure of greater
magnitude in rats fed a very low protein diet (adapted from
Fiorotto and Coward7).
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Effect of rapid reduction of plasma albumin
In some causes of nephrotic syndrome, particularly due
to minimal change disease (MCD), the onset of nephrosis
is abrupt and plasma protein levels can decline rapidly.
A question then is what, if any, are the effects of acute
reductions in plasma oncotic pressure on edema formation?
Plasmapheresis with isotonic fluid replacement has been used
to produce acute reductions in serum oncotic pressure in
order to study the effect of plasma oncotic pressure on blood
volume maintenance. Repeated episodes of plasmapheresis to
produce moderate levels of hypoproteinemia in dogs (mean
4.6 g/dl) led to increased ECFV, no change in blood volume,
and stable renin and aldosterone levels, whereas plasmapher-
esis to severe hypoproteinemia (mean 2.4 g/dl) produced a
decrease in plasma volume and blood volume, an increase in
renin and aldosterone, and a positive sodium balance.14–16
Despite the significant decrease in blood and plasma volume,
there was a significant increase in sodium space (indicating
interstitial fluid volume expansion) in the dogs with severe
hypoproteinemia. These studies suggest that severe acute
hypoproteinemia can cause edema formation and intra-
vascular volume depletion. It is not clear if the explosive
onset of MCD in some patients could cause a similar
reduction in intravascular volume with interstitial fluid
volume expansion. The development of acute renal failure in
a small subset of patients (typically with MCD) suggests that
hypovolemia may play a role, but this cannot be conclusively
proven without formal blood volume measurements.17–21 In a
retrospective review of 95 cases of adult MCD at a single
center, acute renal failure occurred in 24 patients. Those with
acute renal failure were older, were hypertensive, and had
lower serum albumin and more proteinuria compared with
those who did not have acute renal failure.22
CHANGES IN HYDROSTATIC PRESSURE GRADIENTS [PcPi]
Assessment of blood volume in nephrotic patients
There are few studies on this subject and they assess different
end points, which makes comparisons difficult. A significant
issue in the consideration of this problem is the lack of a gold
standard for the assessment of intravascular volume. At least
three methods of intravascular volume assessment have been
utilized in the nephrotic syndrome literature: neurohumoral
hormone assays, blood volume measurement with radio-
active labeling techniques, and presence or absence of
hypovolemic symptoms and signs. This section will review
some of the more important studies assessing blood volume
in the nephrotic syndrome.
Pioneering work on neurohumoral assessment of blood
volume in the nephrotic syndrome was done by Meltzer
et al.,23 who studied patients with untreated nephrotic
syndrome and separated them into two groups by renin
levels. Patients with high renin all had MCD and significantly
higher aldosterone, higher creatinine clearance, lower urine
sodium, and lower serum albumin than the low-renin group.
There was a suggestion of low plasma volume as measured by
125I serum albumin in the high-renin group and elevated
plasma volume in the low-renin group, but no definitive
conclusions could be made because not all subjects had their
plasma volume measured.
In one of the largest studies of nephrotic patients, Geers
et al.24 compared 28 patients with MCD and 24 with
nephrotic syndrome due to other histologic lesions; patients
included all had a low fractional excretion of sodium. The
group with MCD had significantly lower plasma volume
as assessed by 131I-albumin, higher plasma aldosterone,
and lower serum albumin (1.5 vs. 2.1 g/dl) than the other
histologic lesion group, but blood volume was not signifi-
cantly different. There was no correlation between blood
volume and plasma renin activity (PRA) or serum albumin
and blood volume.
In a study of 88 patients with the nephrotic syndrome, 33
of whom had MCD, it was found that plasma and blood
volumes as assessed by 131I-albumin were no different than
those of healthy controls.25 Other studies have also found
that patients with the nephrotic syndrome have normal or
expanded blood volumes.24,26,27
Conversely, there are also studies supporting the presence
of hypovolemia in the nephrotic syndrome. Vande Walle
et al.28 compared children with nephrotic syndrome due to
MCD with those with non-MCD and further divided each
group by the presence or absence of symptoms or signs of
hypovolemia. Patients in both groups with hypovolemic
symptoms had significantly higher levels of norepinephrine,
PRA, and aldosterone, and lower fractional excretion of
sodium than their nonsymptomatic counterparts. When
considering only the group with hypovolemic symptoms, the
non-MCD group (comprising mostly Finnish type nephrotic
syndrome patients) had a lower albumin (0.8 g/dl) and
greater elevation in norepinephrine, PRA, and aldosterone
than did the MCD group whose albumin was 1.5 g/dl. When
analyzing the entire cohort, it was found that there was a
significant negative correlation between aldosterone and both
serum colloid osmotic pressure and fractional excretion of
sodium. Thus, neurohumoral activation was associated with
hypovolemic symptoms and those with the most severe
neurohumoral activation had the lowest serum albumin.
These data suggest that severe hypoalbuminemia is associated
with hypovolemia.
Usberti et al.29 subjected nephrotic patients and control
patients with glomerulonephritis or hematuria to water
loading. The nephrotic patients (8/16 with MCD) had a
significantly lower blood volume and serum albumin than
controls (1.5 vs. 4.0 g/dl). In response to water loading, a
significant direct correlation between plasma osmolality and
arginine vasopressin (AVP) levels was seen in control, but not
in nephrotic patients. In contrast, a significant negative
correlation was seen between blood volume and plasma AVP
in nephrotic but not in control patients. This suggests that a
volume-mediated stimulus was driving vasopressin release in
nephrotic patients. In 1995, Usberti et al.30 studied two
groups of nephrotic patients with normal renal function, one
who had a positive sodium balance and the other in sodium
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balance. The group in positive sodium balance (7/12 with
MCD) had significantly lower measured blood volume, lower
serum albumin (1.4 vs. 2.2 g/dl), and higher renin, angio-
tensin II, and aldosterone than the group in sodium balance.
In both groups there was a direct relationship between serum
albumin and blood volume. As discussed above, this finding
is at odds with other studies.
In summary, most edematous patients with the nephrotic
syndrome have a normal to expanded intravascular volume,
whereas a minority of patients have a depleted intravascular
volume. Those patients with intravascular volume depletion
typically have MCD and more severe hypoalbuminemia. It is
worth noting that although MCD and severe hypoalbumi-
nemia are associated with intravascular volume depletion in
some studies, most patients with MCD and significant
hypoalbuminemia do not show evidence of intravascular
volume depletion.
Neurohormonal changes
Renin, angiotensin II, and aldosterone. The renin, angio-
tensin II, and aldosterone system has frequently been
implicated as a cause of sodium retention in the nephrotic
syndrome, particularly in patients who have intravascular
volume depletion.
Although Geers et al.24 found no correlation between PRA
and blood volume in their large study of nephrotic patients,24
significant negative correlations have been found between
ECFV and log PRA,13 plasma volume and PRA,31 and blood
volume and PRA.30
In a study of nephrotic patients with active sodium
retention with high plasma renin, ACE inhibition with
captopril did not lead to negative sodium balance or weight
loss despite a reduction in plasma aldosterone.32 In a similar
study of nephrotic patients with low and high renin,
captopril failed to produce negative sodium balance despite
a decline in aldosterone levels.33 Several studies have shown
that patients with MCD have higher renin or renin activity
and aldosterone levels than those with other histologic lesions
despite similar blood volumes.23,34 A large study of nephrotic
patients failed to show a difference in PRA in patients with
MCD vs. those with histologic lesions, although those with
MCD did have significantly higher aldosterone concentra-
tions.24 Studies of children with the nephrotic syndrome
showed that patients with hypovolemic symptoms had
greater elevations in renin activity and aldosterone, despite
similar measured blood volumes.27,28,35
Blockade of aldosterone in a small group of nephrotic
patients who were retaining sodium and who were fed a high
salt diet resulted in marginal negative sodium balance.36 This
study did not, however, control for the degree of proteinuria
reduction caused by aldosterone blockade. An inverse relation-
ship has been shown between plasma aldosterone and urinary
sodium excretion by several investigators,28,31,37,38 whereas
other investigators have found no relation.39 It is noteworthy
that in several studies the development of edema occurred
without significant elevations in serum aldosterone levels.24,28,40
The above suggest that renin–angiotensin–aldosterone
system is not a major mechanism of sodium retention in
the nephrotic syndrome. MCD is phenotypically associated
with elevated PRA and aldosterone, although in most cases
the blood volume is not different from those who have other
histologic lesions and normal PRA and aldosterone. It is not
clear if this MCD phenotype suggests an alternate patho-
physiology.
Sympathetic nervous system. The renal vasculature, parti-
cularly the afferent and efferent arterioles, as well as the
tubules are innervated by the sympathetic nervous system.41
Activation of the renal sympathetic nerves causes an increase
in afferent and efferent vascular resistance (independent of
angiotensin II42) and increased renin release with subsequent
increases in angiotensin II, all of which serve to increase
sodium reabsorption.41 In a study of nephrotic rats in the
edema-forming stages, DiBona41 showed that compared with
control rats, nephrotic rats have higher basal renal sympa-
thetic nerve activity, decreased excretion of intravenous
isotonic saline, and less suppression of renal sympathetic
nerve activity following isotonic saline infusion. Following
renal sympathetic denervation, the nephrotic rats had
increased excretion of isotonic saline.
Vasopressin. Patients with the nephrotic syndrome have
been shown to have higher basal AVP levels than controls43
and to have higher AVP levels and reduced free water
clearance in response to water loading vs. controls.29,44
Albumin loading has been shown to reduce serum vasopres-
sin levels in some nephrotic patients, suggesting a volume-
mediated stimulus for vasopressin release.29,45 In a study of
puromycin aminonucleoside (PAN) nephrosis in rats vs.
controls, it was noted that nephrotic rats had higher serum
vasopressin levels and higher hypothalamic AVP mRNA than
controls.46 Vasopressin thus appears to play a role in free
water retention and edema formation in some patients with
the nephrotic syndrome.
Atrial natriuretic peptide. Atrial natriuretic peptide (ANP)
is another hormone that has been implicated in the sodium
retention seen in the nephrotic syndrome. ANP is released by
the atria in response to atrial distension. As the intravascular
volume status is difficult to judge, and nephrotic patients
could have normal, increased, or decreased plasma volumes,
interpretation of ANP levels at baseline and in response to
treatment are difficult.
Rats rendered nephrotic after exposure to adriamycin had
expanded plasma volumes and significantly increased ANP
levels vs. control rats.47
A unilateral adriamycin nephrosis model in rats showed
that the proteinuric kidney was resistant to the diuretic and
natriuretic effects of ANP, whereas the normal kidney had
appropriate natriuresis and diuresis in response to ANP.47
Other groups have also noted diminished natriuresis in
response to ANP infusion in PAN nephrotic rats.48–50 Rats
with nephrosis due to Heymann nephritis and PAN have
been shown to have similar levels of ANP at baseline and after
volume expansion as controls, but had diminished diuresis in
638 Kidney International (2012) 82, 635–642
rev iew EJ Siddall and J Radhakrishnan: Edema formation in nephrotic syndrome
response to volume expansion vs. controls.50,51 In a study of
nephrotic rats, ANP infusion resulted in a blunted natriuresis
and diuresis compared with controls.52 In the same
experiment, renal sympathetic denervation resulted in a
greater diuresis and natriuresis in nephrotic rats in response
to ANP infusion.
A study comparing nephrotic patients with controls
showed a reduced diuretic response to head-out water
immersion despite similar ANP levels.53 This study also
showed lower baseline ANP in nephrotics vs. controls. A
study analyzing nephrotic patients based on their urine
sodium excretion showed that basal ANP correlated with
their basal urinary sodium excretion.
In summary, there is evidence for decreased renal
responsiveness to ANP in some nephrotic patients, whereas
others have low baseline ANP levels that could be pathologic
or could be reflective of an underfilled circulation. Increased
renal sympathetic nerve activity may play a role in ANP
resistance in the nephrotic syndrome.
Role of primary renal sodium retention
Ichikawa et al.54 created a unilateral PAN nephrosis model in
the rat such that one kidney was nephrotic and the other
functioned normally. They showed that although the
nephrotic kidney was proteinuric and sodium avid, the
contralateral normal kidney had no proteinuria and handled
sodium normally as in control rats. This suggested that an
intrarenal defect caused sodium retention. Micropuncture
studies from superficial nephrons showed that there was a
significant increase in sodium reabsorption beyond the distal
convoluted tubule in the nephrotic kidney vs. the normal
kidney.
An increase in cortical collecting duct (CCD) Na/K
ATPase activity55–58 mRNA,58 and amount57 has been shown
in the PAN model of nephrotic syndrome. CCD Na/K ATPase
activity has also been shown to be increased in the HgCl2 and
adriamycin nephrosis models.56 An inverse linear relation-
ship between CCD Na/K ATPase activity and urinary sodium
excretion has been noted.56 The increase in Na/K ATPase
activity was found to be independent of serum aldosterone in
studies of adrenalectomized rats.55,58
The expression58–61 and apical targeting60 of epithelial
sodium channel (ENaC) has been shown to be increased in
the CCD in the PAN model of the nephrotic syndrome and is
aldosterone dependent.58,59 Increased apical targeting of
ENaC in the CCD has also been shown in the HgCl2 model
of the nephrotic syndrome.62 A linear correlation between
plasma aldosterone and ENaC abundance was found in the
PAN model of nephrosis.58 Prevention of hyperaldosteron-
emia by adrenalectomy prevents the increase in apical ENaC
targeting, but does not prevent the development of the
nephrotic syndrome in PAN-treated rats.58,59 Adrenalecto-
mized rats with PAN nephrosis that do not show an increase
in ENaC expression have a similarly low urinary sodium
excretion as adrenal-intact nephrotic rats with increased
ENaC expression.58 Furthermore, treatment with amiloride
prevented the sodium retention in the rat PAN model
of nephrosis,58,63 whereas treatment with an aldosterone
receptor blocker did not.63 It is notable that in the study
by Lourdel et al.58 with adrenalectomized nephrotic rats,
amiloride returned sodium excretion to normal despite the
fact that ENaC expression was not increased.
The above suggests that the observed increase in ENaC
that occurs in animal models of the nephrotic syndrome is
because of aldosterone, and that development of nephrotic
edema is not dependent on aldosterone. The importance of
the ENaC channel in the development of nephrotic edema,
however, is underscored by the reversal of sodium retention
by amiloride in the above animal models. Evidence suggests
that the Na/K-ATPase activity is increased in the nephrotic
syndrome and appears to be important in the sodium
retention seen in the nephrotic syndrome.
Regulation of ENaC occurs through two primary mechan-
isms: regulation of channel density at the apical membrane
and regulation of the open channel probability.64 The ENaC
receptor density is regulated by both aldosterone and vaso-
pressin. Open channel probability is regulated by proteolytic
processing65 and by anionic phospholipids present on the
inner cell membrane.66
ENaC is composed of three subunits: a, b, and g.67 The
a and g have been shown to have regulatory roles.67 An ENaC
channel with uncleaved a and g chains has a low open
channel probability and conducts little sodium.64,67 Proteo-
lytic activation of ENaC is a normal intracellular event with
sequential cleavage of the a and g chains resulting in
progressive increases in its open channel probability.67 Some
ENaC channels have been shown to be present at the apical
membrane in a closed (uncleaved a and g chain) state.67
Carattino et al.68 showed that proteolytic removal of an
inhibitory domain from the g subunit of ENaC by a serine
protease results in near complete activation of ENaC. This
same group then showed that the serine protease plasmin can
activate ENaC through removal of the g inhibitory chain.69
Furthermore, they demonstrated that plasminogen and
plasmin are present in the urine of proteinuric rats with
the metabolic syndrome but not control rats. Simultaneously,
Svenningsen et al.70 showed that plasmin present in the urine
of nephrotic rats and humans can activate ENaC through
removal of an inhibitory g chain domain. Additionally, they
showed that urokinase-type plasminogen activator present in
the rat and human kidney can convert inactive plasminogen
(which is filtered by the nephrotic kidney) to the active-form
plasmin (Figure 2). In the rat PAN nephrosis model, they
showed that amiloride increases urine sodium excretion and
reduces ascites volume. This effect was attributed both to the
ability of amiloride to inhibit ENaC and the ability of
amiloride to inhibit urokinase-type plasminogen activator
and thus reduce the amount of active plasmin present.
The above suggests a dominant role of ENaC in the
sodium retention of the nephrotic syndrome and provides
a rationale for specific diuretic blockade of ENaC. The only
study addressing this showed that a combination of diuretic
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therapy with amiloride and furosemide resulted in greater
natriuresis and weight loss than monotherapy with either
diuretic in 13 pediatric patients.71
These important findings provide a mechanism of an
intrinsic renal defect whereby abnormally filtered proteins in
nephrotic patients can cause sodium retention via ENaC
activation. It also explains the predictable course of recovery
seen in MCD patients treated with steroids. First, there is a
decrement in urinary protein excretion, then a reduction in
aldosterone (urine and serum), followed by natriuresis, and
then diuresis.31,38,72–74
CHANGES IN VASCULAR PERMEABILITY (Kf and r)
The clinical observation that nephrotic patients with similar
degrees of proteinuria can have significant differences in
the degree of edema is curious. It is often assumed that
differences in sodium intake (or diuretic compliance)
account for the individual patient differences in edema, but
patient- and disease-specific factors also seem possible.
One such possibility is an abnormality of systemic
vascular permeability. In 1993, Gamble et al.75 showed that
mercury-in-silastic strain gauge plethysmography could be
used to measure capillary filtration capacity. Whereas
hydraulic conductance (Kf, capillary permeability) can be
measured for a single capillary, capillary filtration capacity
measures hydraulic conductivity of a tissue.76 Lewis et al.76
showed that although the capillary hydrostatic pressure is
normal at the nail bed in nephrotic patients, the capillary
filtration capacity was significantly higher in nephrotic
patients vs. controls. This argues that capillary permeability
is a possible etiology of edema formation in the nephrotic
syndrome. Oqvist et al.77 showed that there was no difference
in clearance of albumin from the plasma to the interstitium
in PAN nephrotic rats vs. controls, which argues against an
abnormality in capillary permeability. Rostoker et al.78 used
the Landis isotope method to assess capillary permeability in
patients with the nephrotic syndrome, healthy controls, and
those with idiopathic cyclic edema, a disease considered to be
related to abnormal vascular permeability. Capillary perme-
ability was found to be significantly higher in those with
idiopathic cyclic edema and the nephrotic syndrome vs.
controls. Another noteworthy finding was the significant
decrease in capillary permeability after treatment with
steroids in patients with MCD.
CONCLUSION
The nephrotic syndrome is characterized by proteinuria,
edema, and hypoalbuminemia. Renal sodium retention and
changes in variables of the Starling equation are fundamental
to the pathophysiology of nephrotic edema. There is evidence
for both intravascular volume expansion (overfilling) and
intravascular volume depletion (underfilling) in patients with
nephrosis.
Microvascular fluid exchange is described using a
formulation of the Starling driving forces (DP and Dp) and
it is through this equation that nephrotic edema is
conceptualized. Previous theories have focused on abnorm-
alities in DP and Dp to explain nephrotic edema. Studies
have shown that hypoalbuminemia (and thus Dp) is not a
likely cause of edema formation in most nephrotic patients
owing to a parallel decrease in interstitial fluid albumin
and an increase in interstitial fluid pressure, both of which
serve to maintain edema driving forces constant. There
is limited evidence suggesting that abnormalities in
vascular permeability (Kf and s) may contribute to edema
formation.
A major advance in our understanding of the pathophy-
siologic basis of edema formation in the nephrotic syndrome
is the discovery that proteinuria can cause primary renal
sodium retention through ENaC activation. This mechanism
is likely active in all patients with nephrotic syndrome,
regardless of their intravascular volume status. Other causes
of primary renal sodium retention include increased renal
efferent sympathetic nerve activity, ANP, and in the
expression and activity of the Na/K ATPase in the collecting
duct in animal models (Figure 3). Furthermore, excess serum
vasopressin levels have been found to contribute to free water
retention in some patients with the nephrotic syndrome. It is
not clear if nephrotic proteinuria underlies any of these other
abnormalities. The renin–angiotensin–aldosterone system
does not appear to be a primary mechanism of renal sodium
retention.
An abundance of data in the last decade has implicated
ENaC as a major factor in edema formation in the nephrotic
syndrome. There are limited animal and human data to
support the use of amiloride in nephrotic patients.58,63,70,71
Amiloride alone would likely not be sufficient for diuresis in
nephrotic patients with significant ECFV expansion given the
limited amount of sodium that is delivered to the collecting
duct. It may, however, be an important adjunct to furosemide
and could have a role in preventing edema in those with
relapsing nephrotic syndrome.
Cortical collecting
duct cell
Urokinase-type
plasminogen activator
Closed ENaC channel
due to the presence of
the γ inhibitory domain
Open ENaC channel
γ Inhibitory
domain
Plasmin
Plasmin
Plasminogen
Lumen Blood
Figure 2 |Plasminogen filtered by the nephrotic glomeruli
is converted to plasmin by urokinase-type plasminogen
activator in the cortical collecting duct cells. Plasmin then
proteolytically removes the c inhibitory domain from
epithelial sodium channel (ENaC), resulting in near full
activation of ENaC.
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Although sodium retention is necessary for edema
formation in the nephrotic syndrome, it is unlikely to be
the sole factor. For instance, patients with Liddle syndrome
who have ENaC activation and sodium retention are not
known to have edema. The observation that patients with
nephrotic syndrome and ECFV expansion to 300% above
baseline have a normal blood volume, whereas those with
chronic renal failure and ECFV expansion of 200% have a
significantly increased blood volume suggests that nephrotic
patients have an additional physiologic abnormality that
favors preferential expansion of the interstitial space in
response to an increase in ECFV.13 It is possible that a critical
reduction in the capillary-interstitial oncotic pressure gra-
dient or abnormalities in vascular permeability are also
important in edema formation.
Many problems remain in this field. First, it is difficult to
obtain unambiguous measurement of the driving forces
across the capillary in that the interstitial space is not readily
accessible. But the greatest difficulty is to obtain a direct
measurement of the capillary permeability function. Finally,
in most studies the nephrotic syndrome is considered a
uniform entity throughout its course. However, it is quite
likely that the physiology of salt retention and edema has
different phases. The initiating events have already passed by
the time the patient presents to the physician with edema.
This is the phase where the pathogenesis of edema needs to
be studied; yet, most studies address a later phase (by
necessity), and hence what is being studied is often a steady
state that is reached after renal and neurohumoral compen-
sation has set in.
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